{"filing":{"accession_number":"0001193125-26-377696","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-31","primary_document":"d110660d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526377696/d110660d8k.htm"},"events":[{"id":30842,"run_id":28282,"accession_number":"0001193125-26-377696","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"BioMarin completed the acquisition of Alesta Therapeutics B.V. via a share purchase transaction on August 31, 2026, making Alesta a wholly owned subsidiary. This is a material acquisition disclosed under Item 8.01 (Other Events) as a completion of a previously announced M\u0026A transaction, consistent with the ma_activity event type covering entry into, completion, or termination of material acquisitions.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33566,"accession_number":"0001193125-26-377696","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"BioMarin completed the acquisition of Alesta Therapeutics B.V. via a share purchase transaction on August 31, 2026, making Alesta a wholly owned subsidiary. This is a material acquisition disclosed under Item 8.01 (Other Events) as a completion of a previously announced M\u0026A transaction, consistent with the ma_activity event type covering entry into, completion, or termination of material acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:27:31.449502+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33566,"accession_number":"0001193125-26-377696","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"BioMarin completed the acquisition of Alesta Therapeutics B.V. via a share purchase transaction on August 31, 2026, making Alesta a wholly owned subsidiary. This is a material acquisition disclosed under Item 8.01 (Other Events) as a completion of a previously announced M\u0026A transaction, consistent with the ma_activity event type covering entry into, completion, or termination of material acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:27:31.449502+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-01"}]}